Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castlemans disease with multiorgan failure: Report of two cases

AIDS

Volumn 22, Issue 13, 2008, Pages 1685-1687

  Buchler, Tomas ^a   Dubash, Suraiya ^a   Lee, Victor ^a   Chilton, Daniella ^b   Cartledge, Jonathan ^b   Isaacson, Peter ^a   Tedder, Richard S ^b   Lee, Siow M ^a,c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; C REACTIVE PROTEIN; CORTICOSTEROID; DEXAMETHASONE; EFAVIRENZ; EMTRICITABINE; GANCICLOVIR; LOPINAVIR PLUS RITONAVIR; RITUXIMAB; TENOFOVIR; VINCRISTINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; DEATH; DISEASE COURSE; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LETTER; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REMISSION; SEPSIS; VIRUS LOAD; FATALITY; HUMAN IMMUNODEFICIENCY VIRUS 1; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL; FATAL OUTCOME; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; MALE; MULTIPLE ORGAN FAILURE; TREATMENT FAILURE;

EID: 52249122417     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f7371f     Document Type: Letter

References (7)

1. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004; 43:698-704.
2. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129:3-17.
3. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 2000; 96:2069-2073.
4. Hall PA, Donaghy M, Cotter FE, Stansfeld AG, Levison DA. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology 1989; 14:333-346.
5. Ohyashiki JH, Ohyashiki K, Kawakubo K, Serizawa H, Abe K, Mikata A, et al. Molecular genetic, cytogenetic, and immuno-phenotypic analyses in Castleman's disease of the plasma cell type. Am J Clin Pathol 1994; 101:290-295.
6. Collins LS, Fowler A, Tong CY, de Ruiter A. Multicentric Castleman's disease in HIV infection. Int J STD AIDS 2006; 17:19-24.
7. Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102:2786-2788.